Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TE3 bleomycin infusion schedule toxicity study in good prognosis metastatic testicular germ cell cancer
ISRCTN08648791Phase 3Completed
- Sponsor
- Barts Health NHS Trust
- Start
- Jul 2003
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of bleomycin in Germ Cell Testicular Cancer (2 arms), sponsored by Barts Health NHS Trust. Primary endpoint: Pulmonary toxicity. Started Jul 2003; status: completed.
02
Drugs
bleomycin
03
Conditions
Germ Cell Testicular Cancer
Beyond the preview
Go deeper on ISRCTN08648791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN08648791.